Endoscopic surveillance and ablative therapy for periampullary adenomas

Ian D. Norton, Alex Geller, Bret Thomas Petersen, Darius Sorbi, Christopher J. Gostout

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

OBJECTIVES: Periampullary adenomas are an increasingly recognized condition, both in those with familial adenomatous polyposis syndromes (FAP) as well as sporadic cases. Endoscopic management has been advocated for these lesions without differentiating between these two patient groups regarding aim of therapy. The aims of this study were to determine the safety and effectiveness of endoscopic surveillance and ablative therapy of periampullary adenomas in patients with both sporadic and FAP-associated lesions. METHODS: Retrospective analysis of 59 patients with FAP and 32 with sporadic lesions who were all enrolled in a program of endoscopic surveillance and ablative therapy. Median follow-up was 24 months (range, 1-134 months). RESULTS: Ampullary ablative therapy has resulted in return to normal histology in 44 and 34% of sporadic and FAP-associated lesions, respectively. Complications of endoscopic therapy were mild in 12 patients and severe in 3 patients: the latter category involved one occurrence of asymptomatic duodenal stenosis and one occurrence of postcoagulation syndrome - both after Nd-YAG laser therapy - and necrotizing pancreatitis after ampullary biopsy in one patient. Thirteen patients have been referred for surgical intervention. There has been no mortality and no cases of advanced malignancy missed by endoscopy. CONCLUSIONS: Endoscopic surveillance and ablative therapy of periampullary lesions is safe and can be effective, although eradication of ampullary tissue requires multiple ablative sessions.

Original languageEnglish (US)
Pages (from-to)101-106
Number of pages6
JournalAmerican Journal of Gastroenterology
Volume96
Issue number1
DOIs
StatePublished - 2001

Fingerprint

Adenomatous Polyposis Coli
Adenoma
Therapeutics
Solid-State Lasers
Laser Therapy
Pancreatitis
Endoscopy
Histology
Biopsy
Safety
Mortality

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Endoscopic surveillance and ablative therapy for periampullary adenomas. / Norton, Ian D.; Geller, Alex; Petersen, Bret Thomas; Sorbi, Darius; Gostout, Christopher J.

In: American Journal of Gastroenterology, Vol. 96, No. 1, 2001, p. 101-106.

Research output: Contribution to journalArticle

Norton, Ian D. ; Geller, Alex ; Petersen, Bret Thomas ; Sorbi, Darius ; Gostout, Christopher J. / Endoscopic surveillance and ablative therapy for periampullary adenomas. In: American Journal of Gastroenterology. 2001 ; Vol. 96, No. 1. pp. 101-106.
@article{c722900142fc46f6a93b92221bc5d6f1,
title = "Endoscopic surveillance and ablative therapy for periampullary adenomas",
abstract = "OBJECTIVES: Periampullary adenomas are an increasingly recognized condition, both in those with familial adenomatous polyposis syndromes (FAP) as well as sporadic cases. Endoscopic management has been advocated for these lesions without differentiating between these two patient groups regarding aim of therapy. The aims of this study were to determine the safety and effectiveness of endoscopic surveillance and ablative therapy of periampullary adenomas in patients with both sporadic and FAP-associated lesions. METHODS: Retrospective analysis of 59 patients with FAP and 32 with sporadic lesions who were all enrolled in a program of endoscopic surveillance and ablative therapy. Median follow-up was 24 months (range, 1-134 months). RESULTS: Ampullary ablative therapy has resulted in return to normal histology in 44 and 34{\%} of sporadic and FAP-associated lesions, respectively. Complications of endoscopic therapy were mild in 12 patients and severe in 3 patients: the latter category involved one occurrence of asymptomatic duodenal stenosis and one occurrence of postcoagulation syndrome - both after Nd-YAG laser therapy - and necrotizing pancreatitis after ampullary biopsy in one patient. Thirteen patients have been referred for surgical intervention. There has been no mortality and no cases of advanced malignancy missed by endoscopy. CONCLUSIONS: Endoscopic surveillance and ablative therapy of periampullary lesions is safe and can be effective, although eradication of ampullary tissue requires multiple ablative sessions.",
author = "Norton, {Ian D.} and Alex Geller and Petersen, {Bret Thomas} and Darius Sorbi and Gostout, {Christopher J.}",
year = "2001",
doi = "10.1016/S0002-9270(00)02151-1",
language = "English (US)",
volume = "96",
pages = "101--106",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Endoscopic surveillance and ablative therapy for periampullary adenomas

AU - Norton, Ian D.

AU - Geller, Alex

AU - Petersen, Bret Thomas

AU - Sorbi, Darius

AU - Gostout, Christopher J.

PY - 2001

Y1 - 2001

N2 - OBJECTIVES: Periampullary adenomas are an increasingly recognized condition, both in those with familial adenomatous polyposis syndromes (FAP) as well as sporadic cases. Endoscopic management has been advocated for these lesions without differentiating between these two patient groups regarding aim of therapy. The aims of this study were to determine the safety and effectiveness of endoscopic surveillance and ablative therapy of periampullary adenomas in patients with both sporadic and FAP-associated lesions. METHODS: Retrospective analysis of 59 patients with FAP and 32 with sporadic lesions who were all enrolled in a program of endoscopic surveillance and ablative therapy. Median follow-up was 24 months (range, 1-134 months). RESULTS: Ampullary ablative therapy has resulted in return to normal histology in 44 and 34% of sporadic and FAP-associated lesions, respectively. Complications of endoscopic therapy were mild in 12 patients and severe in 3 patients: the latter category involved one occurrence of asymptomatic duodenal stenosis and one occurrence of postcoagulation syndrome - both after Nd-YAG laser therapy - and necrotizing pancreatitis after ampullary biopsy in one patient. Thirteen patients have been referred for surgical intervention. There has been no mortality and no cases of advanced malignancy missed by endoscopy. CONCLUSIONS: Endoscopic surveillance and ablative therapy of periampullary lesions is safe and can be effective, although eradication of ampullary tissue requires multiple ablative sessions.

AB - OBJECTIVES: Periampullary adenomas are an increasingly recognized condition, both in those with familial adenomatous polyposis syndromes (FAP) as well as sporadic cases. Endoscopic management has been advocated for these lesions without differentiating between these two patient groups regarding aim of therapy. The aims of this study were to determine the safety and effectiveness of endoscopic surveillance and ablative therapy of periampullary adenomas in patients with both sporadic and FAP-associated lesions. METHODS: Retrospective analysis of 59 patients with FAP and 32 with sporadic lesions who were all enrolled in a program of endoscopic surveillance and ablative therapy. Median follow-up was 24 months (range, 1-134 months). RESULTS: Ampullary ablative therapy has resulted in return to normal histology in 44 and 34% of sporadic and FAP-associated lesions, respectively. Complications of endoscopic therapy were mild in 12 patients and severe in 3 patients: the latter category involved one occurrence of asymptomatic duodenal stenosis and one occurrence of postcoagulation syndrome - both after Nd-YAG laser therapy - and necrotizing pancreatitis after ampullary biopsy in one patient. Thirteen patients have been referred for surgical intervention. There has been no mortality and no cases of advanced malignancy missed by endoscopy. CONCLUSIONS: Endoscopic surveillance and ablative therapy of periampullary lesions is safe and can be effective, although eradication of ampullary tissue requires multiple ablative sessions.

UR - http://www.scopus.com/inward/record.url?scp=0035138950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035138950&partnerID=8YFLogxK

U2 - 10.1016/S0002-9270(00)02151-1

DO - 10.1016/S0002-9270(00)02151-1

M3 - Article

C2 - 11197237

AN - SCOPUS:0035138950

VL - 96

SP - 101

EP - 106

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 1

ER -